Hypertensive patients are highly heterogeneous in cardiovascular prognosis and treatment responses. A better classification system with phenomapping of clinical features would be of greater value to identify patients at higher risk of developing cardiovascular outcomes and direct individual decision-making for antihypertensive treatment.
Methods
An unsupervised, data-driven cluster analysis was performed for all baseline variables related to cardiovascular outcomes and treatment responses in subjects from the Systolic Blood Pressure Intervention Trial (SPRINT), in order to identify distinct subgroups with maximal within-group similarities and between-group differences. Cox regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for cardiovascular outcomes and compare the effect of intensive antihypertensive treatment in different clusters.
Results
Four replicable clusters of patients were identified: cluster 1 (index hypertensives); cluster 2 (chronic kidney disease hypertensives); cluster 3 (obese hypertensives) and cluster 4 (extra risky hypertensives). In terms of prognosis, individuals in cluster 4 had the highest risk of developing primary outcomes. In terms of treatment responses, intensive antihypertensive treatment was shown to be beneficial only in cluster 4 (HR 0.73, 95% CI 0.55–0.98) and cluster 1 (HR 0.54, 95% CI 0.37–0.79) and was associated with an increased risk of severe adverse effects in cluster 2 (HR 1.18, 95% CI 1.05–1.32).
Conclusion
Using a data-driven approach, SPRINT subjects can be stratified into four phenotypically distinct subgroups with different profiles on cardiovascular prognoses and responses to intensive antihypertensive treatment. Of note, these results should be taken as hypothesis generating that warrant further validation in future prospective studies.
ForouzanfarMHLiuPRothGA, et al.Global burden of hypertension and systolic blood pressure of at least 110 to 115 mmHg, 1990–2015. JAMA2017; 317: 165–182.
2.
ForouzanfarMHAlexanderL, et al.Global Burden of Disease Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet2015; 386: 2287–2323.
3.
MillsKTBundyJDKellyTN, et al.Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation2016; 134: 441–450.
4.
WrightJTJrWilliamsonJD, et al.The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med2015; 373: 2103–2116.
5.
WheltonPKCareyRMAronowWS, et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol2018; 71: e127–e248.
6.
WilliamsBManciaGSpieringW, et al.2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J2018; 39: 3021–3104.
7.
JonesDWWeatherlyLHallJE. SPRINT: What remains unanswered and where do we go from here?Hypertension2016; 67: 261–262.
8.
YouroukovaVMDimitrovaDGValerievaAD, et al.Phenotypes determined by cluster analysis in moderate to severe bronchial asthma. Folia Med (Plovdiv)2017; 59: 165–173.
9.
AhlqvistEStormPKarajamakiA, et al.Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol2018; 6: 361–369.
10.
ShapiroBPAmbrosiusWTBlackshearJL, et al.Impact of intensive versus standard blood pressure management by tertiles of blood pressure in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension2018; 71: 1064–1074.
11.
ThomopoulosCParatiGZanchettiA. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens2014; 32: 2285–2295.
12.
BeddhuSChertowGMCheungAK, et al.Influence of baseline diastolic blood pressure on effects of intensive compared with standard blood pressure control. Circulation2018; 137: 134–143.
13.
UpadhyaBRoccoMLewisCE, et al.Effect of intensive blood pressure treatment on heart failure events in the Systolic Blood Pressure Reduction Intervention Trial. Circ Heart Fail2017; 10: e003613–e003613. . DOI: 10.1161/CIRCHEARTFAILURE.116.003613.
14.
BerkelmansGFVisserenFLJaspersNE, et al.SPRINT trial: It’s not just the blood pressure!. Eur J Prev Cardiol2017; 24: 1482–1484.
15.
ErikssonMCarlbergBPennlertJ, et al.Time trends and socioeconomic differences in blood pressure levels: the Northern Sweden MONICA study 1994–2014. Eur J Prev Cardiol2017; 24: 1473–1481.
16.
VeronesiGTunstall-PedoeHFerrarioMM, et al.Combined effect of educational status and cardiovascular risk factors on the incidence of coronary heart disease and stroke in European cohorts: implications for prevention. Eur J Prev Cardiol2017; 24: 437–445.
17.
FlegalKMGraubardBIWilliamsonDF, et al.Excess deaths associated with underweight, overweight, and obesity. JAMA2005; 293: 1861–1867.
18.
FlegalKMGraubardBIWilliamsonDF, et al.Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA2007; 298: 2028–2037.
19.
FlegalKMKitBKOrpanaH, et al.Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA2013; 309: 71–82.
20.
Di AngelantonioEBhupathirajuSN, et al.The Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet2016; 388: 776–786.
21.
HeXLiuCChenY, et al.Overweight without central obesity, cardiovascular risk, and all-cause mortality. Mayo Clin Proc2018; 93: 709–720.
22.
AzimiACharlotMGTorp-PedersenC, et al.Moderate overweight is beneficial and severe obesity detrimental for patients with documented atherosclerotic heart disease. Heart2013; 99: 655–660.
23.
CarboneSLavieCJArenaR. Obesity and heart failure: focus on the obesity paradox. Mayo Clin Proc2017; 92: 266–279.
24.
LavieCJDe SchutterAPartoP, et al.Obesity and prevalence of cardiovascular diseases and prognosis – the obesity paradox updated. Prog Cardiovasc Dis2016; 58: 537–547.
25.
SharmaALavieCJBorerJS, et al.Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol2015; 115: 1428–1434.
26.
Oxlund CS, Pareek M, Rasmussen BSB, et al. Body mass index, intensive blood pressure management, and cardiovascular events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Med 2019; pii: S0002-9343(19)30133-0. DOI: 10.1016/j.amjmed.2019.01.024.
27.
RaoGPowell-WileyTMAnchetaI, et al.Identification of obesity and cardiovascular risk in ethnically and racially diverse populations: a scientific statement from the American Heart Association. Circulation2015; 132: 457–472.
28.
PiepoliMFHoesAWAgewallS, et al.2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J2016; 37: 2315–2381.
29.
BundyJDLiCStuchlikP, et al.Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol2017; 2: 775–781.
30.
EttehadDEmdinCAKiranA, et al.Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet2016; 387: 957–967.
31.
XieXAtkinsELvJ, et al.Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet2016; 387: 435–443.
32.
Blood Pressure Lowering Treatment Trialists Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet2014; 384: 591–598.
33.
ThomopoulosCParatiGZanchettiA. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk – overview and meta-analyses of randomized trials. J Hypertens2014; 32: 2305–2314.
34.
ThomopoulosCParatiGZanchettiA. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels – overview and meta-analyses of randomized trials. J Hypertens2014; 32: 2296–2304.
35.
WheelerDCBeckerGJ. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?Kidney Int2013; 83: 377–383.
36.
AmbrosiusWTSinkKMFoyCG, et al.The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials2014; 11: 532–546.
37.
KlahrSLeveyASBeckGJ, et al.The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med1994; 330: 877–884.
38.
KovesdyCPLuJLMolnarMZ, et al.Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease. JAMA Intern Med2014; 174: 1442–1449.
39.
CheungAKRahmanMReboussinDM, et al.Effects of intensive BP control in CKD. J Am Soc Nephrol2017; 28: 2812–2823.
40.
KuEGassmanJAppelLJ, et al.BP control and long-term risk of ESRD and mortality. J Am Soc Nephrol2017; 28: 671–677.
41.
MalhotraRNguyenHABenaventeO, et al.Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. JAMA Intern Med2017; 177: 1498–1505.
42.
ObiYKalantar-ZadehKShintaniA, et al.Estimated glomerular filtration rate and the risk-benefit profile of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial. J Intern Med2018; 283: 314–327.
43.
BressAPTannerRMHessR, et al.Generalizability of SPRINT results to the U.S. adult population. J Am Coll Cardiol2016; 67: 463–472.
44.
KjeldsenSEMariampillaiJENilssonPM. Optimal blood pressure target in diabetic and nondiabetic hypertensive patients. Circ Res2018; 123: 528–530.
45.
OparilSCushmanWCJohnsonKC, et al.Sprinting toward the optimal blood pressure target for hypertensive patients. Circ Res2018; 123: 531–534.
